Last reviewed · How we verify
Therapy of hemorrhagic disease of the newborn — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Vitamin K1 | Phytonadione | Pfizer Inc. | Vitamin K [EPC] | Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects) |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
- — Vitamin K1 · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer Inc. · 1 drug in Therapy of hemorrhagic disease of the newborn
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Therapy of hemorrhagic disease of the newborn:
- Therapy of hemorrhagic disease of the newborn treatment updates — RSS
- Therapy of hemorrhagic disease of the newborn treatment updates — Atom
- Therapy of hemorrhagic disease of the newborn treatment updates — JSON
Cite this brief
Drug Landscape (2026). Therapy of hemorrhagic disease of the newborn — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/therapy-of-hemorrhagic-disease-of-the-newborn. Accessed 2026-06-10.
Related
- Therapy of hemorrhagic disease of the newborn full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing